Selected as Implementing Institution for Ministry of Health and Welfare Project Following TIPS by Ministry of SMEs and Startups

Adel, a biotech company developing new drugs for degenerative brain diseases, announced on June 11 that it has been selected as the final implementing institution for a new task in the Ministry of Health and Welfare's 'Dementia Medical Technology Research and Development Project.' This marks a consecutive win in government R&D projects, following its selection earlier this year for the Ministry of SMEs and Startups’ TIPS (Tech Incubator Program for Startups) Deep Tech Track R&D project.


Adel Secures Consecutive Government R&D Projects, Accelerates Dementia Medical Technology Development View original image

Through the project selected by the Ministry of SMEs and Startups in April, Adel is receiving a total research grant of 1.5 billion won from the government to build a 'next-generation brain delivery technology platform' for the efficient delivery of drugs into the brain. The company is currently conducting initial-stage research to verify the brain delivery efficiency of drugs using cell and animal models.


The newly selected project from the Ministry of Health and Welfare is overseen by the Korea Health Industry Development Institute. As the lead research institution, Adel will receive a total of 2.2 billion won in research funding over three years starting this year to develop 'ADEL-Y04,' an ApoE4-targeted antibody therapeutic, at the preclinical stage. ApoE4 is a major genetic risk factor found in about 65% of Alzheimer's disease patients and is a core pathogenic substance that induces neurotoxicity, accelerating cognitive decline.


ADEL-Y04, the subject of this project, has demonstrated efficacy in inhibiting toxicity and improving cognitive function in animal studies, and optimization for human administration has also been completed. Through this project, Adel plans to finalize the verification of the drug’s safety and efficacy and secure the data necessary for entry into Phase 1 clinical trials.


If the project advances to the clinical stage, it is expected that Adel will be able to reduce ARIA (amyloid-related imaging abnormalities) side effects, which have been cited as a limitation of existing antibody therapeutics, or confirm the potential for combination therapy with other drugs.


Adel has built its R&D track record with government support. Its acetylated tau-targeted antibody therapeutic 'ADEL-Y01,' which was licensed out to global pharmaceutical company Sanofi for a total of 1.04 billion dollars, was also developed with government support. ADEL-Y01 successfully completed Phase 1a clinical trials through the national R&D project for dementia research and development.


Seungyong Yoon, CEO of Adel, stated, "Being selected as the implementing institution for both the TIPS Deep Tech project and the Dementia Medical Technology R&D Project is recognition of our strategy for developing ApoE4-specific new drugs and the validity of our next-generation brain delivery technology platform research. Based on government R&D support, we will successfully complete preclinical development and platform advancement research as planned."



Meanwhile, Adel is undergoing a technical evaluation for a technology-special listing to enter the KOSDAQ market. It has selected Samsung Securities and Mirae Asset Securities as its lead underwriters.


This content was produced with the assistance of AI translation services.

© The Asia Business Daily. All rights reserved. Unauthorized AI training and use prohibited.

Today’s Briefing